dsm-firmenich Targets 2026-2027 Growth After Transformation Completion
Event summary
- dsm-firmenich completed its transformation into a consumer-focused company after divesting Animal Nutrition & Health.
- The company delivered €175 million in cost synergies and plans to accelerate performance in 2026-2027.
- 2026 outlook includes 2–4% organic sales growth, adjusted EBITDA margin around 20%, and cash conversion of 11–12%.
- Mid-term target for Adjusted Gross Operating Free Cash Flow increased from ≥10% to ≥14% starting 2028.
- Share repurchase program of €540 million announced, with €500 million to reduce issued capital.
The big picture
dsm-firmenich's shift to a fully consumer-focused company marks a strategic pivot following the divestment of its Animal Nutrition & Health segment. The company now aims to capitalize on its streamlined portfolio and cost synergies to drive performance in a challenging macro-economic environment. With a €540 million share repurchase program and increased mid-term cash flow targets, dsm-firmenich is positioning itself for accelerated growth in the nutrition, health, and beauty sectors.
What we're watching
- Execution Risk
- How dsm-firmenich will deliver on its multi-lever plan to drive growth and expand EBITDA margins amid macro-economic challenges.
- Market Conditions
- Whether cautious consumer demand and adverse FX effects will persist beyond Q1 2026, impacting full-year performance.
- Capital Allocation
- The pace at which dsm-firmenich normalizes capital expenditure and reduces working capital while maintaining growth targets.
Related topics